Anti-Infective Pharmaceuticals Market in India 2012

  • Product Code:
    RP-ID-10080121
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    82
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-13

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

ccs

Market Overview:

Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for anti-infective drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, increasing number of vaccine approvals, increase in health insurances and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part, has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief classification of the anti infectives market. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, increasing vaccine approvals, increase in health insurances and introduction of newer and better drugs. The key challenges include pricing pressure and logistic problems in the vaccine market.

The government initiatives section gives a brief description of the different control programmes undertaken by the Government. It also analyses the efforts to reduce drug prices, changes in the customs duty structure and the various PPP projects undertaken by the Government.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti infective drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Anti Infective Pharmaceutical industry.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the production of adult vaccines and improvement in the logistics of the vaccine market will help the companies increase their customer base. Also, efficient marketing strategies, like strategic alliances of foreign companies with local manufacturers, or tie-ups of domestic manufacturers with Government bodies and non-governmental organizations will increase the profitability of the companies.


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

.

Page 1: Executive summary

Introduction
Page 2: Classification of anti infective pharmaceutical market
Page 3: Types of anti infective drugs

Market Overview
Page 4: Global Anti-Infective Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-15e),
Page 5: Indian Anti-Infective Pharmaceuticals Market- Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

Drivers & Challenges
Page 6: Summary
Page 7-10: Drivers
Page 11: Challenges

Government initiatives
Page 12: Summary
Page 13-20: Government Initiatives

Market value chain, regulation and patents
Page 21: Pharmaceutical value chain
Page 22: Phases of clinical trials
Page 23-24: Drug regulations
Page 25: Regulatory framework
Page 26-28: List of patent approvals

Competition
Page 29: Market Competition - Porter's Five Forces Analysis
Page 30- 71: Major Public Companies
Abbott India Limited
Cipla Limited
Claris Lifesciences Limited
GlaxoSmithKline Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited
Lupin Limited
Novartis India Limited
Panacea Biotec Limited
Pfizer Limited
Ranbaxy Laboratories Limited
Sun Pharmaceutical Industries Limited
Torrent Pharmaceuticals Limited
Wockhardt Limited
Gilead Sciences Inc.
Page 72- 80: Major Private Companies
Bristol-Myers Squibb India Private Limited
Takeda Pharmaceuticals India Private Limited
Watson Pharma Private Limited
Page 81: Recent Developments

Strategic Recommendation
Page 82: Strategic Recommendations
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
1. Abbott India Limited
2. Cipla Limited
3. Claris Lifesciences Limited
4. GlaxoSmithKline Pharmaceuticals Limited
5. Glenmark Pharmaceuticals Limited
6. Lupin Limited
7. Novartis India Limited
8. Panacea Biotec Limited
9. Pfizer Limited
10. Ranbaxy Laboratories Limited
11. Sun Pharmaceutical Industries Limited
12. Torrent Pharmaceuticals Limited
13. Wockhardt Limited
14. Gilead Sciences Inc.
15. Bristol-Myers Squibb India Private Limited
16. Takeda Pharmaceuticals India Private Limited
17. Watson Pharma Private Limited
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports